Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma.

doi:10.1172/JCI178446

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma.

The Journal of clinical investigation - 16 Sept 2025

Tiago Manoela, Purwin Timothy J, Stefanski Casey D, da Silva Renaira Oliveira, Fane Mitchell E, Chhabra Yash, Haj Jelan I, Teh Jessica Lf, Kadamb Rama, Cai Weijia, Rosenbaum Sheera R, Chua Vivian, Hacohen Nir, Davies Michael A, Villanueva Jessie, Chervoneva Inna, Weeraratna Ashani T, Erkes Dan A, Capparelli Claudia, Aguirre-Ghiso Julio A, Aplin Andrew E

Abstract excerpt

Despite the success of targeted inhibitors in cutaneous melanoma, therapeutic responses are limited by the aged tumor microenvironment and drug-tolerant residual cells. Given the similarities between drug tolerance and cellular dormancy, we studied the dormancy marker, nuclear receptor subfamily 2 group F member 1 (NR2F1), in response to BRAF-V600E inhibitors (BRAFi) plus MEK inhibitors (MEKi) in BRAF-mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Neoplasm Invasiveness

Share to Neoplasm Proteins

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 40955663
DOI: 10.1172/JCI178446
PMCID: PMC12435839

Genes

NR2F1
BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma.PMID 40955663Read ↗

Midkine Drives Reawakening of Dormant Melanoma MetastasesSemantic proximity Read ↗

NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell ProliferationSemantic proximity Read ↗

Lineage commitment pathways epigenetically oppose oncogenic Gαq/11-YAP1 signaling in dormant disseminated uveal melanomaSemantic proximity Read ↗

Zebrafish MITF-Low Melanoma Subtype Models Reveal Transcriptional Subclusters and MITF-Independent Residual DiseaseSemantic proximity Read ↗

The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma.Semantic proximity Read ↗

NF1 Loss Remodels Tumor Niches for Immune EvasionSemantic proximity Read ↗

Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant MelanomaSemantic proximity Read ↗

Toward Minimal Residual Disease-Directed Therapy in Melanoma.Semantic proximity Read ↗

Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors.Semantic proximity Read ↗

A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling.Semantic proximity Read ↗

Targeting DDR1 and DDR2 overcomes matrix-mediated melanoma cell adaptation to BRAF-targeted therapySemantic proximity Read ↗

Melanoma-intrinsic NR2F6 activity regulates anti-tumor immunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.